0001104659-23-111094.txt : 20231024 0001104659-23-111094.hdr.sgml : 20231024 20231024160657 ACCESSION NUMBER: 0001104659-23-111094 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231020 FILED AS OF DATE: 20231024 DATE AS OF CHANGE: 20231024 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ZACCARDELLI DAVID CENTRAL INDEX KEY: 0001627642 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38067 FILM NUMBER: 231342772 MAIL ADDRESS: STREET 1: 300 TRI STATE INTERNATIONAL STREET 2: SUITE 272 CITY: LINCOLNSHIRE STATE: IL ZIP: 60069 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Verona Pharma plc CENTRAL INDEX KEY: 0001657312 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3 MORE LONDON RIVERSIDE CITY: LONDON STATE: X0 ZIP: SE1 2RE BUSINESS PHONE: 011-44-0-2032834200 MAIL ADDRESS: STREET 1: 3 MORE LONDON RIVERSIDE CITY: LONDON STATE: X0 ZIP: SE1 2RE 4 1 tm2329036-4_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2023-10-20 0 0001657312 Verona Pharma plc VRNA 0001627642 ZACCARDELLI DAVID 3 MORE LONDON RIVERSIDE LONDON X0 SE1 2RE UNITED KINGDOM 1 1 0 0 President and CEO 0 Ordinary Shares 2023-10-20 4 A 0 800000 0 A 17231800 D Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Represents an award of Restricted Share Units ("RSUs"), each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer. The RSUs vest over four years, with 200,000 RSUs vesting on November 1, 2024 and the balance vesting in 12 equal quarterly installments thereafter. Consists of (i) 6,711,840 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 838,980 ADSs); and (ii) 10,519,960 Ordinary Shares underlying 1,314,995 ADSs. /s/ Claire Poll, Attorney-in-fact for David Zaccardelli 2023-10-24